Navigation Links
ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
Date:2/26/2008

growth in pancreatic and breast cancer models and recognizes CD9 on CD34+CD38- leukemic cancer stem cells." Experimental and Molecular Therapeutics 32, Tuesday, April 15, 2008, 8:00 AM

Abstract Number 3995:

"A monoclonal antibody targeting CD59 (AR36A36.11.1), enhances complement activity and exhibits potent in vivo efficacy in multiple human cancer models." Experimental and Molecular Therapeutics 32, Tuesday, April 15, 2008, 8:00 AM

About ARIUS

ARIUS is a biotechnology company discovering and developing the next wave of antibody therapeutics. Established in 1999, ARIUS has built a proprietary technology platform, FunctionFIRST(TM), that rapidly identifies and selects antibodies based on their functional ability to affect disease. This antibody generation engine has enabled ARIUS to assemble a portfolio of more than 500 antibody candidates. In addition to the antibodies it is developing in-house, ARIUS has ongoing partnerships with key biotechnology and drug development companies. ARIUS is listed on the TSX under the symbol "ARI". For further information, visit http://www.ariusresearch.com

Forward-Looking Statements

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause our actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward-looking statements in this release include, but are not limited to, ARIUS successfully advancing its new product programs as well as licensing opportunities. These statements are only predictions and actual events or results may differ materially. Factors that could cause such actual events or results expressed or implied by such forward-looking statements to differ material
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
2. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
3. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
4. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
5. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
6. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
7. ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
8. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
9. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
10. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
11. ARIUS to present at Chinese Global Financial Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 In recent years, growing suspicion ... in product development and promotion has led to unprecedented ... fueled by concerns about the insidious impact of commercialization ... spectacular fines to the world’s biggest pharmas for illegal ...
(Date:1/14/2014)... 2014   Kinaxis ®, provider of RapidResponse ®, a ... operations planning ( S&OP ) service, is proud to be ... will be held at the Hilton San Diego Bayfront, January ... Elisabeth Kaszas , Director of Supply Chain at Amgen, ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 During the 1600’s ... known as “The Doctor’s Plague.” In this time period, doctors ... This led, at times, to the death of vulnerable patients. ... don’t know that they may be unwittingly transmitting herpes viruses ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Holloway America ... database of material test reports (MTRs) for all pressure ... Documenting test results is particularly important for equipment that ... The MTR Library features search functionality that allows authorized ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 2Pressure Vessel Design and Fabrication Company Builds Database for Material Test Reports 3
... Diseases and,Disorders, OLDSMAR, Fla., Jan. 29 ... ("Cryo-Cell" or the "Company"), one of the,largest ... today announced that,it has formalized a research ... ("Saneron") that represents an important milestone in,efforts ...
... RESEARCH TRIANGLE PARK, N.C., Jan. 29 ,Merial Limited and ... under which Merial will screen a Chimerix chemical library ... agreement, Merial has an,option to negotiate a license with ... "This collaboration with Chimerix provides us with an opportunity ...
... year end; no equity financings expected in 2008, ... continue in,2008; latest data for all programs to be ... Expansion of research and development investment in pharmacological, ... 2008, CRANBURY, N.J., Jan. 29 Amicus Therapeutics,(Nasdaq: ...
Cached Biology Technology:Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc. 2Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc. 3Cryo-Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics, Inc. 4Merial to Screen Chimerix' Chemical Library for Animal Health Drug Leads 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 2Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 3Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 4Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 5Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 6Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 7Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 8Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 9Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 10Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 11Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 12Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 13Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements 14
(Date:4/18/2014)... R.I. [Brown University] Asteroid and comet impacts can ... on regional or even global scales. But new research ... the signatures of ancient life at the time of ... geologist Pete Schultz has found fragments of leaves and ... several ancient impacts in Argentina. The material could provide ...
(Date:4/17/2014)... April 17 In the most densely forested and ... reflect two centuries of human needs, values and practices. ... clearing forests for agriculture and development, have set the ... U.S. Forest Service study reports. , The report ... and management needs in the Northern United States ...
(Date:4/17/2014)... Respiratory syncytial virus (RSV) is a leading cause ... in very young and elderly populations. Despite great ... cells through the fusion protein RSV F, which ... that prevent bundle formation limit RSV infection in ... degradation. In this issue of the Journal ...
Breaking Biology News(10 mins):Impact glass stores biodata for millions of years 2Impact glass stores biodata for millions of years 3Five anthropogenic factors that will radically alter northern forests in 50 years 2Five anthropogenic factors that will radically alter northern forests in 50 years 3JCI online ahead of print table of contents for April 17, 2014 2JCI online ahead of print table of contents for April 17, 2014 3JCI online ahead of print table of contents for April 17, 2014 4JCI online ahead of print table of contents for April 17, 2014 5JCI online ahead of print table of contents for April 17, 2014 6
... Could straw houses be the buildings of the future? ... testing this summer by constructing a "BaleHaus" made of prefabricated ... And people around the world will be able to watch ... www.bath.ac.uk/features/balehaus/ ,- part of a site which will also ...
... Fla. (July 27, 2009) An Italian research team, ... (18:4), which is now available on-line without charge ... derived from human placenta may ultimately play a role ... fibrosis and fibrotic diseases caused by tuberculosis, chemical exposure, ...
... Ph.D., from the Louisiana Universities Marine Consortium (LUMCON), found the ... be smaller than forecasted, measuring 3,000 square miles. However the ... the sea floor, was severe where it did occur, extending ... Earlier this summer, NOAA-sponsored forecast models developed by R. ...
Cached Biology News:University has grand designs to build a house of straw 2University has grand designs to build a house of straw 3Placenta-derived stem cells may help sufferers of lung diseases 2Smaller than expected, but severe, dead zone in Gulf of Mexico 2
Carrier-Free Recombinant Human Flt-3/Flk-2 Ligand (Flt3/Flk2 Ligand, Flt3L, Flt3-L, Flk2L, Flk2-L) 100 ug...
Gap junction protein, beta 2, 26kDa (connexin 26) Antigen: Peptide...
IKKbeta/IKK-2 Polyclonal Antibody 100 ug affinity purified rabbit polyclonal antibody. Reacts with human. Tested in Western blotting....
...
Biology Products: